A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention

OBJECTIVE: To assess the safety and efficacy of AMG 301, an inhibitor of the pituitary adenylate cyclase-activating polypeptide (PACAP)-1 (PAC1) receptor, for prevention of migraine. METHODS: In a double-blind trial, patients were randomized 4:3:3 to placebo, AMG 301 210 mg every 4 weeks, or AMG 301...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashina, Messoud, Doležil, David, Bonner, Jo H, Zhou, Lifen, Klatt, Jan, Picard, Hernan, Mikol, Daniel D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786389/
https://www.ncbi.nlm.nih.gov/pubmed/33231489
http://dx.doi.org/10.1177/0333102420970889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786389/
https://www.ncbi.nlm.nih.gov/pubmed/33231489
http://dx.doi.org/10.1177/0333102420970889

Ejemplares similares